Receptor variants in human prostate cancer cells

International Journal of Molecular Sciences

Volumn 13, Issue 9, 2012, Pages 11530-11542

  Zengerling, Friedemann ^a,b   Streicher, Wolfgang ^a   Schrader, Andres J ^a   Schrader, Mark ^a   Nitzsche, Bianca ^b   Cronauer, Marcus V ^a   Höpfner, Michael ^b  

^a UNIVERSITY OF ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Castration resistant prostate cancer; Sorafenib; Truncated androgen receptor variants

Indexed keywords

ANDROGEN RECEPTOR; PROTEASOME; SORAFENIB; ANDROGEN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; ISOPROTEIN; NICOTINAMIDE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; BINDING SITE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANDROGENS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84866889249     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms130911530     Document Type: Article

References (40)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Bluemn, E.G.; Nelson, P.S. The androgen/androgen receptor axis in prostate cancer. Curr. Opin. Oncol. 2012, 24, 251-257.
3. Feldman, B.J.; Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1, 34-45.
4. Locke, J.A.; Guns, E.S.; Lubik, A.A.; Adomat, H.H.; Hendy, S.C.; Wood, C.A.; Ettinger, S.L.; Gleave, M.E.; Nelson, C.C. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008, 68, 6407-6415.
5. Haile, S.; Sadar, M.D. Androgen receptor and its splice variants in prostate cancer. Cell Mol. Life Sci. 2011, 68, 3971-3981.
6. Ceraline, J.; Cruchant, M.D.; Erdmann, E.; Erbs, P.; Kurtz, J.E.; Duclos, B.; Jacqmin, D.; Chopin, D.; Bergerat, J.P. Constitutive activation of the androgen receptor by a point mutation in the hinge region: A new mechanism for androgen-independent growth in prostate cancer. Int. J. Cancer 2004, 108, 152-157.
7. Libertini, S.J.; Tepper, C.G.; Rodriguez, V.; Asmuth, D.M.; Kung, H.J.; Mudryj, M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res. 2007, 67, 9001-9005.
8. Hornberg, E.; Ylitalo, E.B.; Crnalic, S.; Antti, H.; Stattin, P.; Widmark, A.; Bergh, A.; Wikstrom, P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011, 6, e19059.
9. Zhang, X.; Morrissey, C.; Sun, S.; Ketchandji, M.; Nelson, P.S.; True, L.D.; Vakar-Lopez, F.; Vessella, R.L.; Plymate, S.R. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011, 6, e27970.
10. Harada, N.; Inoue, K.; Yamaji, R.; Nakano, Y.; Inui, H. Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells. Cancer Sci. 2012, 103, 1022-1027.
11. Chan, S.C.; Li, Y.; Dehm, S.M. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J. Biol. Chem. 2012, 287, 19736-19749.
12. Mostaghel, E.A.; Marck, B.T.; Plymate, S.R.; Vessella, R.L.; Balk, S.; Matsumoto, A.M.; Nelson, P.S.; Montgomery, R.B. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 2011, 17, 5913-5925.
13. Gioeli, D.; Paschal, B.M. Post-translational modification of the androgen receptor. Mol. Cell Endocrinol. 2012, 352, 70-78.
14. Weigel, N.L.; Moore, N.L. Steroid receptor phosphorylation: A key modulator of multiple receptor functions. Mol. Endocrinol. 2007, 21, 2311-2319.
15. Oh, S.J.; Erb, H.H.; Hobisch, A.; Santer, F.R.; Culig, Z. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr. Relat. Cancer 2012, 19, 305-319.
16. Gaddipati, J.P.; McLeod, D.G.; Heidenberg, H.B.; Sesterhenn, I.A.; Finger, M.J.; Moul, J.W.; Srivastava, S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994, 54, 2861-2864.
17. Streicher, W.; Zengerling, F.; Laschak, M.; Weidemann, W.; Hopfner, M.; Schrader, A.J.; Jentzmik, F.; Schrader, M.; Cronauer, M.V. AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J. Urol. 2012, 30, 333-339.
18. Lapouge, G.; Erdmann, E.; Marcias, G.; Jagla, M.; Monge, A.; Kessler, P.; Serra, S.; Lang, H.; Jacqmin, D.; Bergerat, J.P.; et al. Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-A new paradigm for cooperation among prostate tumor cells. Int. J. Cancer 2007, 121, 1238-1244.
19. Watson, P.A.; Chen, Y.F.; Balbas, M.D.; Wongvipat, J.; Socci, N.D.; Viale, A.; Kim, K.; Sawyers, C.L. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl. Acad. Sci. USA 2010, 107, 16759-16765.
20. Chen, S.; Xu, Y.; Yuan, X.; Bubley, G.J.; Balk, S.P. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc. Natl. Acad. Sci. USA 2006, 103, 15969-15974.
21. Rinnab, L.; Schütz, S.V.; Diesch, J.; Schmid, E.; Kufer, R.; Hautmann, R.E.; Spindler, K.D.; Cronauer, M.V. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: Are GSK inhibitors therapeutically useful? Neoplasia 2008, 10, 624-634.
22. Agoulnik, I.U.; Bingman, W.E., III; Nakka, M.; Li, W.; Wang, Q.; Liu, X.S.; Brown, M.; Weigel, N.L. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol. Endocrinol. 2008, 22, 2420-2432.
23. Hu, R.; Dunn, T.A.; Wei, S.; Isharwal, S.; Veltri, R.W.; Humphreys, E.; Han, M.; Partin, A.W.; Vessella, R.L.; Isaacs, W.B. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69, 16-22.
24. Schütz, S.V.; Cronauer, M.V.; Rinnab, L. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J. Cell Biochem. 2010, 109, 1192-1200.
25. Schütz, S.V.; Schrader, A.J.; Zengerling, F.; Genze, F.; Cronauer, M.V.; Schrader, M. Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One 2011, 6, e25341.
26. Jain, G.; Voogdt, C.; Tobias, A.; Spindler, K.D.; Moller, P.; Cronauer, M.V.; Marienfeld, R.B. IkappaB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. Neoplasia 2012, 14, 178-189.
27. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
28. Cronauer, M.V.; Ince, Y.; Engers, R.; Rinnab, L.; Weidemann, W.; Suschek, C.V.; Burchardt, M.; Kleinert, H.; Wiedenmann, J.; Sies, H. et al. Nitric oxide-mediated inhibition of androgen receptor activity: Possible implications for prostate cancer progression. Oncogene 2007, 26, 1875-1884.
29. Sonpavde, G.; Periman, P.O.; Bernold, D.; Weckstein, D.; Fleming, M.T.; Galsky, M.D.; Berry, W.R.; Zhan, F.; Boehm, K.A.; Asmar, L., et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 2009, 21, 319-324.
30. Dror Michaelson, M.; Regan, M.M.; Oh, W.K.; Kaufman, D.S.; Olivier, K.; Michaelson, S.Z.; Spicer, B.; Gurski, C.; Kantoff, P.W.; Smith, M.R. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 2009, 20, 913-920.
31. Araujo, J.C.; Mathew, P.; Armstrong, A.J.; Braud, E.L.; Posadas, E.; Lonberg, M.; Gallick, G.E.; Trudel, G.C.; Paliwal, P.; Agrawal, S. et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 2012, 118, 63-71.
32. Mathew, P.; Thall, P.F.; Bucana, C.D.; Oh, W.K.; Morris, M.J.; Jones, D.M.; Johnson, M.M.; Wen, S.; Pagliaro, L.C.; Tannir, N.M. et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin. Cancer Res. 2007, 13, 5816-5824.
33. Dahut, W.L.; Scripture, C.; Posadas, E.; Jain, L.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Yu, Y.; Cao, L.; Steinberg, S.M. et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 2008, 14, 209-214.
34. Steinbild, S.; Mross, K.; Frost, A.; Morant, R.; Gillessen, S.; Dittrich, C.; Strumberg, D.; Hochhaus, A.; Hanauske, A.R.; Edler, L. et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br. J. Cancer 2007, 97, 1480-1485.
35. Chi, K.N.; Ellard, S.L.; Hotte, S.J.; Czaykowski, P.; Moore, M.; Ruether, J.D.; Schell, A.J.; Taylor, S.; Hansen, C.; Gauthier, I. et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann. Oncol. 2008, 19, 746-751.
36. Aragon-Ching, J.B.; Jain, L.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Steinberg, S.M.; Draper, D.; Venitz, J.; Jones, E.; Chen, C.C. et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. Br. J. Urol. Int. 2009, 103, 1636-1640.
37. Safarinejad, M.R. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study. Urol. Oncol. 2008, 28, 21-27.
38. Huang, R.; Chen, X.Q.; Huang, Y.; Chen, N.; Zeng, H. The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J. Androl. 2010, 12, 527-534.
39. Ullen, A.; Farnebo, M.; Thyrell, L.; Mahmoudi, S.; Kharaziha, P.; Lennartsson, L.; Grander, D.; Panaretakis, T.; Nilsson, S. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int. J. Oncol. 2010, 37, 15-20.
40. Beardsley, E.K.; Hotte, S.J.; North, S.; Ellard, S.L.; Winquist, E.; Kollmannsberger, C.; Mukherjee, S.D.; Chi, K.N. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest. New Drugs 2012, 30, 1652-1659.